IDEX Co. (NYSE:IEX) Expected to Post Quarterly Sales of $614.26 Million

Share on StockTwits

Equities analysts expect IDEX Co. (NYSE:IEX) to post sales of $614.26 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for IDEX’s earnings, with estimates ranging from $608.00 million to $621.00 million. IDEX posted sales of $614.09 million in the same quarter last year, which suggests a positive year-over-year growth rate of 0%. The company is scheduled to report its next quarterly earnings report on Tuesday, February 4th.

On average, analysts expect that IDEX will report full-year sales of $2.50 billion for the current financial year, with estimates ranging from $2.50 billion to $2.51 billion. For the next financial year, analysts expect that the business will post sales of $2.53 billion, with estimates ranging from $2.50 billion to $2.59 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for IDEX.

IDEX (NYSE:IEX) last posted its earnings results on Tuesday, October 29th. The industrial products company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.06. IDEX had a return on equity of 21.28% and a net margin of 17.05%. The company had revenue of $624.20 million during the quarter, compared to analysts’ expectations of $641.66 million. During the same quarter last year, the firm earned $1.41 earnings per share. The firm’s quarterly revenue was up .2% compared to the same quarter last year.

Several analysts recently issued reports on the stock. ValuEngine lowered shares of IDEX from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st. Rosenblatt Securities reaffirmed a “buy” rating and set a $185.00 target price on shares of IDEX in a research note on Wednesday. Finally, Citigroup initiated coverage on shares of IDEX in a research note on Monday, September 30th. They issued a “neutral” rating and a $175.00 price target on the stock. Eight research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. IDEX has a consensus rating of “Hold” and an average target price of $175.57.

NYSE IEX opened at $160.27 on Friday. The stock has a fifty day simple moving average of $160.19 and a 200-day simple moving average of $162.44. The company has a current ratio of 3.21, a quick ratio of 2.39 and a debt-to-equity ratio of 0.39. The stock has a market cap of $11.97 billion, a PE ratio of 29.62, a P/E/G ratio of 2.80 and a beta of 1.21. IDEX has a twelve month low of $117.72 and a twelve month high of $173.84.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 30th. Stockholders of record on Wednesday, January 15th will be paid a $0.50 dividend. The ex-dividend date of this dividend is Tuesday, January 14th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.25%. IDEX’s payout ratio is presently 36.97%.

In related news, SVP Daniel J. Salliotte sold 23,842 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $161.62, for a total transaction of $3,853,344.04. Following the completion of the transaction, the senior vice president now directly owns 30,358 shares in the company, valued at approximately $4,906,459.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ernest J. Mrozek sold 6,650 shares of IDEX stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $160.24, for a total value of $1,065,596.00. Following the completion of the transaction, the director now directly owns 16,255 shares of the company’s stock, valued at $2,604,701.20. The disclosure for this sale can be found here. Insiders sold a total of 54,543 shares of company stock worth $8,833,294 in the last quarter. Company insiders own 1.20% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of IEX. Krane Funds Advisors LLC purchased a new stake in IDEX during the 2nd quarter worth approximately $27,000. Squar Milner Financial Services LLC increased its position in shares of IDEX by 376.5% during the third quarter. Squar Milner Financial Services LLC now owns 162 shares of the industrial products company’s stock worth $26,000 after acquiring an additional 128 shares during the period. Cullen Frost Bankers Inc. purchased a new stake in shares of IDEX during the second quarter worth $33,000. Global Retirement Partners LLC acquired a new stake in shares of IDEX in the third quarter valued at $42,000. Finally, SRS Capital Advisors Inc. acquired a new stake in shares of IDEX in the second quarter valued at $44,000. 97.31% of the stock is owned by institutional investors and hedge funds.

About IDEX

IDEX Corporation, through its subsidiaries, operates as an applied solutions company worldwide. The company operates through three segments: Fluid & Metering Technologies (FMT), Health & Science Technologies (HST), and Fire & Safety/Diversified Products (FSDP). The FMT segment designs, produces, and distributes positive displacement pumps, flow meters, injectors, and other fluid-handling pump modules and systems, as well as offers flow monitoring and other services for the food, chemical, general industrial, water and wastewater, agricultural, and energy industries.

See Also: What is the definition of market timing?

Get a free copy of the Zacks research report on IDEX (IEX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for IDEX (NYSE:IEX)

Receive News & Ratings for IDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEX and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Spectral Medical  versus Dynatronics  Head-To-Head Survey
Spectral Medical versus Dynatronics Head-To-Head Survey
Contrasting Cypress Energy Partners  & Superior Energy Services
Contrasting Cypress Energy Partners & Superior Energy Services
Esquire Financial  & Its Rivals Financial Analysis
Esquire Financial & Its Rivals Financial Analysis
Analyzing Columbia Financial  & Its Peers
Analyzing Columbia Financial & Its Peers
PacWest Bancorp  Forecasted to Post Q1 2020 Earnings of $0.85 Per Share
PacWest Bancorp Forecasted to Post Q1 2020 Earnings of $0.85 Per Share
Reviewing Titan Pharmaceuticals  and Gritstone Oncology
Reviewing Titan Pharmaceuticals and Gritstone Oncology


 
© 2006-2020 Zolmax.